Pre-existing Antibodies Identified as Key Barrier to Phage Therapy Efficacy in Landmark Australian Study
核心洞察
Researchers at The Alfred (搜索) and Monash University published the first VICPhage patient case in Nature Medicine, detailing phage therapy for a 22-year-old cystic fibrosis (搜索) patient with multidrug-resistant bacterial infections.
Pre-existing antibodies in the patient neutralized therapeutic bacteriophages (搜索) before they could kill the infection, revealing a critical mechanism of treatment failure.
The team rapidly developed a screening process to test future patients for anti-phage antibodies, enabling personalized treatment adaptation.
A groundbreaking case study from Melbourne has revealed that pre-existing antibodies can neutralize therapeutic bacteriophages (搜索) before they reach their bacterial targets, a finding that could reshape how phage therapy is developed and administered for patients with life-threatening, drug-resistant infections.
Published in Nature Medicine, the paper details the first patient treated under VICPhage—a clinical partnership between The Alfred (搜索) hospital and Monash University, and one of the first Australian programs to offer end-to-end phage therapy services.
The patient, a 22-year-old man with cystic fibrosis (搜索), had been suffering from severe, recurrent infections caused by bacteria resistant to almost all available antibiotics. After exhausting conventional treatment options, clinicians sought compassionate-use approval from Australia's Therapeutic Goods Administration (TGA) to administer phage therapy.
Immune Neutralization Halts Treatment
Despite the promise of bacteriophages (搜索)—viruses that specifically target and destroy bacteria—the therapy did not produce the desired clinical response. Dr. Fernando Gordillo-Altamirano, a postdoctoral researcher in the Peleg Phage Translational Lab and first author of the paper, explained the root cause.
"We discovered that phage therapy didn't work in this patient because he had pre-existing antibodies against the phage," Dr. Gordillo-Altamirano said. "These antibodies destroyed the phages before they could kill the infection."
This finding marks the first documented case from the VICPhage program where host immune factors directly interfered with phage efficacy, providing critical insights into the complex interplay between the immune system, bacteria, and therapeutic phages.
Rapid Translation to Clinical Practice
In response to this discovery, the research team swiftly developed a methodology to screen subsequent patients for pre-existing antibodies against specific phages prior to treatment. This screening process allows clinicians to adapt therapy by selecting phages less susceptible to neutralization by a given patient's immune system.
"We were swiftly able to determine how to test subsequent patients to see if they already have antibodies against particular phages, in order to adapt our treatment," Dr. Gordillo-Altamirano noted.
Implications for Future Clinical Trials
Professor Anton Peleg, Director of the Department of Infectious Diseases at The Alfred (搜索) and Monash University, co-lead of VICPhage, and senior author of the paper, emphasized that the findings extend beyond individual patient care to the broader design of phage therapy research.
"The work we are doing builds on the foundation of generations past but takes advantage of the huge innovations in science and technology to harness its potential for personalized treatments that could revolutionize the way we treat infectious disease," Professor Peleg said.
He indicated that the next stage of research would require large randomized controlled trials to evaluate the efficacy of phage therapy against placebo treatments, with the immune findings from this case informing trial protocols.
Building Infrastructure for Phage Therapy
Professor Jeremy Barr, from the School of Biological Sciences and Centre to Impact AMR at Monash University, co-leads VICPhage and heads the Monash Phage Foundry, where clinical-grade phages are produced. He described the case as pivotal for the field.
"This was a pivotal phage therapy case of a very difficult-to-treat infection," Professor Barr said. "What we have learnt here will allow us to provide faster and more effective phage treatments in the future."
Professor Barr added that the team, together with collaborators around Australia, is reviewing methodologies, phage production approaches, and data collection from treated patients across the country. "There's still a long road ahead, but it's one we are determined to travel as this therapy has the potential to save hundreds of lives for patients suffering from serious and life-threatening infectious disease."
A Contemporary Approach to an Old Idea
While phages were first used therapeutically in the early 1900s, they were largely abandoned with the introduction of antibiotics. As antimicrobial resistance continues to escalate globally, phage therapy has re-emerged as a promising alternative. VICPhage is pioneering a modern approach, offering compassionate-use phage therapy services while simultaneously advancing multicentre clinical trials.
Currently, Australian clinicians must apply to the TGA for compassionate-use approval before administering phage therapy, demonstrating that patients have exhausted all other treatment options and that the infection threatens life, limb, or function.
The VICPhage team's work underscores both the promise and the complexity of phage therapy, highlighting that successful implementation requires not only effective phages but also a nuanced understanding of each patient's immunological landscape.